A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma

BACKGROUND: Most ovarian cancer patients are diagnosed at a late stage with 85% of them relapsing after surgery and standard chemotherapy; for this reason, new treatments are urgently needed. Ovarian cancer has become a candidate for immunotherapy by reason of their expression of shared tumor-associ...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarivalasis, Apostolos, Boudousquié, Caroline, Balint, Klara, Stevenson, Brian J., Gannon, Philippe O., Iancu, Emanuela Marina, Rossier, Laetitia, Martin Lluesma, Silvia, Mathevet, Patrice, Sempoux, Christine, Coukos, George, Dafni, Urania, Harari, Alexandre, Bassani-Sternberg, Michal, Kandalaft, Lana E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6880492/
https://www.ncbi.nlm.nih.gov/pubmed/31771601
http://dx.doi.org/10.1186/s12967-019-02133-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6880492/
https://www.ncbi.nlm.nih.gov/pubmed/31771601
http://dx.doi.org/10.1186/s12967-019-02133-w

Ejemplares similares